A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Hospital Authority, Hong Kong.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
The University of Hong Kong
Information provided by:
Hospital Authority, Hong Kong
ClinicalTrials.gov Identifier:
NCT00404794
First received: November 27, 2006
Last updated: July 6, 2010
Last verified: July 2010

November 27, 2006
July 6, 2010
November 2005
Not Provided
Proteinuria
Same as current
Complete list of historical versions of study NCT00404794 on ClinicalTrials.gov Archive Site
Adverse effects
Same as current
Not Provided
Not Provided
 
A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis
A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Tacrolimus and Corticosteroid as Immunosuppressive Treatment for Lupus Membranous Nephritis

This is a prospective randomized open-label pilot study to compare mycophenolate mofetil in combination with corticosteroid treatment and tacrolimus in combination with corticosteroid treatment in membranous lupus nephritis. The change in urine protein excretion will be the primary outcome studied. The study duration will be 24 months for each patient.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Lupus Nephritis
  • Glomerulonephritis, Membranous
  • Drug: prednisolone and mycophenolate mofetil
  • Drug: prednisolone and tacrolimus
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
October 2009
Not Provided

Inclusion Criteria:

  • abnormal urine protein excretion and biopsy-proven membranous lupus nephritis
Both
18 Years to 65 Years
Not Provided
Contact: Daniel TM Chan, Prof (852) 28554542 dtmchan@hkucc.hku.hk
China
 
NCT00404794
UW05-205 T/868, HARECCTR0500003
Not Provided
Not Provided
Hospital Authority, Hong Kong
The University of Hong Kong
Principal Investigator: Daniel TM Chan, Prof Department of Medicine, Queen Mary Hospital
Hospital Authority, Hong Kong
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP